C$20.12
0.89%
Toronto, Oct 10, 09:57 pm CET
ISIN
CA0717051076
Symbol
BLCO

Bausch + Lomb Stock price

C$20.12
-0.76 3.64% 1M
+4.22 26.54% 6M
-5.84 22.50% YTD
-6.09 23.24% 1Y
-1.27 5.94% 3Y
-5.38 21.10% 5Y
-5.38 21.10% 10Y
-5.38 21.10% 20Y
Toronto, Closing price Fri, Oct 10 2025
-0.18 0.89%
ISIN
CA0717051076
Symbol
BLCO

Key metrics

Basic
Market capitalization
C$7.1b
Enterprise Value
C$13.7b
Net debt
C$6.6b
Cash
C$372.8m
Shares outstanding
353.8m
Valuation (TTM | estimate)
P/E
negative | 26.6
P/S
1.0 | 1.0
EV/Sales
2.0 | 1.9
EV/FCF
negative
P/B
0.8
Financial Health
Equity Ratio
48.1%
Return on Equity
-4.9%
ROCE
0.8%
ROIC
0.5%
Debt/Equity
0.8
Financials (TTM | estimate)
Revenue
C$6.9b | C$7.3b
EBITDA
C$524.1m | C$1.2b
EBIT
C$140.1m | C$864.2m
Net Income
C$-382.6m | C$267.5m
Free Cash Flow
C$-231.2m
Growth (TTM | estimate)
Revenue
8.8% | 8.3%
EBITDA
-20.8% | 78.4%
EBIT
-49.2% | 199.3%
Net Income
40.1% | 160.2%
Free Cash Flow
-20.4%
Margin (TTM | estimate)
Gross
59.7%
EBITDA
7.7% | 17.0%
EBIT
2.0%
Net
-5.6% | 3.7%
Free Cash Flow
-3.4%
More
EPS
C$-1.1
FCF per Share
C$-0.7
Short interest
0.2%
Employees
14k
Rev per Employee
C$500.0k
Show more

Is Bausch + Lomb a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,999 stocks worldwide.

Bausch + Lomb Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Bausch + Lomb forecast:

10x Buy
50%
9x Hold
45%
1x Sell
5%

Analyst Opinions

20 Analysts have issued a Bausch + Lomb forecast:

Buy
50%
Hold
45%
Sell
5%

Financial data from Bausch + Lomb

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
6,854 6,854
9% 9%
100%
- Direct Costs 2,764 2,764
12% 12%
40%
4,091 4,091
7% 7%
60%
- Selling and Administrative Expenses 3,062 3,062
13% 13%
45%
- Research and Development Expense 503 503
9% 9%
7%
524 524
21% 21%
8%
- Depreciation and Amortization 384 384
0% 0%
6%
EBIT (Operating Income) EBIT 140 140
49% 49%
2%
Net Profit -383 -383
40% 40%
-6%

In millions CAD.

Don't miss a Thing! We will send you all news about Bausch + Lomb directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Head office Canada
CEO Brenton Saunders
Employees 13,500
Founded 1853
Website ir.bausch.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today